Clinical Trial: Effect of Refnot on Immunity in Cancer Patients
Study Status: COMPLETED
Recruit Status: COMPLETED
Condition: Solid Tumor
Study Type: INTERVENTIONAL
Official Title: Effect of Refnot on Immunity in Cancer Patients
Brief Summary:
The study was planned to include disseminated patients with various solid tumors (melanoma, soft tissue sarcoma, breast cancer, colon cancer, etc.).The study drug was administered subcutaneously at a dose of 400,000 IU once a day, 3 times a week (every other day), for 4 weeks.In the absence of disease progression - an additional 4 weeks.
Read more